Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement

 Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement

Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement

Shots:

  • Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement
  • Cologuard was approved by US FDA in August 2014 and is included in American Cancer Society’s (2018) colorectal cancer screening guidelines. It is indicated to screen adults (aged 45 yrs. and older) who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool
  • Cologuard is the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. It is an accurate, at-home colon cancer screening option and is uniquely positioned to support screening during this time and after the pandemic abates

Click here to­ read full press release/ article | Ref: PR Newswire | Image: WMTV

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post